ClinicalTrials.gg
Not yet recruitingNCT07435636MOSAICUpdated Nov 4, 2026

Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis

A Phase 2 interventional study of Oral Decitabine and Tetrahydrouridine and Matched Placebo (Capsules) in Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance and Clonal Hematopoiesis, sponsored by Clinical Hub for Interventional Research (CHOIR). Not yet recruiting at 3 sites in Australia. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Clinical Hub for Interventional Research (CHOIR) · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

Clonal hematopoiesis (CH) is characterized by the overproduction of blood cells derived from a single hematopoietic stem and progenitor cell (HSPC) harboring certain somatic mutations. It is linked to serious outcomes, including cardiovascular disease, myeloid neoplasm (MN), and increased mortality.

Clonal Cytopenia of Uncertain Significance (CCUS) is a CH subtype characterized by associated persistent cytopenia. It affects approximately 10 % of people over 70 and is the most advanced precursor state with the highest risk of progressing to MN. There is an unmet need to determine whether modifying CH can prevent adverse outcomes. Current blood cancer therapies are too toxic for precursor conditions like CH.

MOSAIC is a randomized double-blind placebo-controlled trial that will test a novel low-dose oral epigenetic therapy-decitabine with tetrahydrouridine (Dec+THU) in CCUS. It has shown targeted, non-cytotoxic reversal of common CH mutations in preclinical and early-phase studies.

The goal is to develop a safe and effective therapy in CCUS that restores normal blood cell production and prevents progression.

02

Conditions studied

  • Clonal Cytopenia of Uncertain Significance
  • CCUS Clonal Cytopenia of Undetermined Significance
  • Clonal Hematopoiesis

Browse trials for

Keywords

  • MOSAIC
  • CH
  • Modulation of stem cell differentiation
  • CCUS
  • persistent cytopenia
  • clonal hematopoiesis
  • clonal haematopoiesis
  • Clonal Cytopenia of Uncertain Significance
03

In context

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

This study's planned enrollment of 80 is above the median of 34 across 51 interventional studies indexed under Cytopenia.

Browse Cytopenia studies →

Lead sponsor

Clinical Hub for Interventional Research (CHOIR) is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 60 and ≤ 85 years old
  2. Clonal Cytopenia of Uncertain Significance (CCUS), defined by all of the following:

    a. Persistent cytopenia, present on at least two occasions, at least four months apart, with no other cause identified: i. (Hb) \< 120 g/L in people born female, and \< 130 g/L in people born male ii. count \< 150 x 109/L iii. (ANC) \< 1.8 x109/L b. Clonal hematopoiesis (CH) driver mutation confirmed by custom gene panel mutation analysis c. absence of features diagnostic for defined myeloid neoplasm (MN) on bone marrow examination

  3. CH driver mutation variant allele fraction (VAF) of ≥ 10%
  4. For participants living with :

    1. Receiving and adherent to suppressive antiretroviral therapy for at least 12 months
    2. CD4+T cell count ≥ 0.35 x 109/L
    3. HIV viral load \< 50 copies/mL

6. Performance status by (ECOG) Criteria of 0 or 1 7. For participants who are of , or whose partners are of childbearing potential:

  1. Agreement to use at least two highly effective (per Clinical Trial Facilitation Group) methods throughout the course of the trial, and for 6 months following the last dose of trial drug
  2. Refrain from donating eggs or sperm during the same period
  3. Confirmation of a negative serum pregnancy test at screening and at the beginning of each treatment cycle visit (for female participants of childbearing potential) 8. Provision of signed written document prior to any trial-related assessments or procedures being carried out

Exclusion criteria

Exclusion Criteria:

  1. ANC \< 0.5 x109/L
  2. Serum (Aspartate transaminase) or ALT (Alanine aminotransaminase) > 3 times of
  3. Calculated or measured ≤ 50 mL/min
  4. Significant active cardiac disease within the previous 6 months, including:

    1. (NYHA) class III or IV congestive heart failure
    2. Unstable angina or angina requiring surgical or medical intervention
    3. Myocardial infarction
    4. New or unstable cardiac arrhythmia. Stable or controlled arrhythmias are permitted
  5. Active systemic infections:

    1. Infection with ongoing signs/symptoms related to the infection without improvement despite appropriate anti-infectives
    2. Active infection (HBV) (defined as HBsAg positive, or HBcAb positive and measurable HBV DNA; participants who are HBcAb positive must have HBV DNA assayed during screening)
    3. Active Virus (HCV) will be ineligible if there is clinical hepatic dysfunction or other systemic manifestations of HCV disease, or if the hepatic eligibility parameters above are not met. Consideration should be given to curative HCV therapy prior to enrolment in consultation with HCV clinician
  6. Any history of hematological or solid in previous the 5 years unless the participant has been free of disease for ≥ 36 months. However, participants with the following history/concurrent conditions are not excluded:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix
    3. Carcinoma in situ of the breast
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, [TNM] clinical staging system)
  7. Known to trial drugs or their constituents
  8. Currently enrolled in the treatment phase of an interventional trial.
  9. Pregnant or breast-feeding individuals
  10. Any condition not already outlined above which, in the opinion of the Principal Investigator, would place the participant at risk if they participated or would jeopardize adherence, follow up, or confound the ability to interpret trial data
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    active drug

    Oral combination capsules containing both decitabine and tetrahydrouridine (Dec+THU)

    Drug: Oral Decitabine and Tetrahydrouridine

  • Placebo comparator
    matched placebo

    Drug: Matched Placebo (Capsules)

Interventions

  • DrugOral Decitabine and Tetrahydrouridine

    Drug pages: DecitabineStudies of DecitabineDecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TetrahydrouridineStudies of TetrahydrouridineTetrahydrouridine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After randomization, participants will receive oral combination capsules containing decitabine (Dec) (2.5 mg) and tetrahydrouridine (THU) (125 mg) minitablets, or matched placebo. Trial medication will be dispensed on Day 1 of each cycle and taken once weekly (Days 1, 8, 15, 22) for 24 weeks. Dosing of Dec+THU will follow weight-based dosing at 0.2mg/kg and 10mg/kg respectively. This is a phase II, multicenter, double-blind, placebo-controlled randomized trial

  • DrugMatched Placebo (Capsules)

    Placebo capsules will be administered on the same schedule and dosing frequency to the active drug

06

What researchers measure

Primary outcomes

  1. Change in variant allele fraction (VAF) in peripheral blood mononuclear cells (PBMC) at the completion of 24 weeks of treatment.

    Change in variant allele fraction (VAF) in peripheral blood mononuclear cells (PBMC), at the completion of 24 weeks of treatment, will be used to compare the evolution of clonal cytopenia of undetermined significance (CCUS) in individuals with CCUS and associated clinically significant cytopenia receiving Dec+THU compared with those receiving placebo, by intention-to-treat analysis. VAF will be assessed by capture sequencing using the Auckland Myeloid Gene Panel V4 (AMGPV4)

    Time frame: End of Treatment (Week 24)

Secondary outcomes

  1. Number and proportion of participants: a) experiencing Grade 3, 4 and 5 adverse events (AE) b) discontinuing treatment due to AEs or Serious Adverse Events (SAEs) c) living with HIV maintaining HIV Viral Load (VL) suppression

    The safety profile of Dec+THU treatment will be evaluated at the end of 24 weeks of treatment. Each cycle is 28 days.

    Time frame: End of Treatment (Week 24)

  2. Number and proportion of participants completing planned 24 weeks of treatment.

    The feasibility of Dec+THU treatment will be evaluated by number and proportion of participants completing planned 24 weeks of treatment

    Time frame: End of Treatment (Week 24)

  3. Number and proportion of participants with cytopenia response

    Participant cytopenia response will be assessed and measured according to the 2018 International Working Group (IWG) criteria with comparison between the Dec+THU treatment group and the placebo group

    Time frame: End of Treatment (Week 24) and Follow Up 1 (Week 48)

  4. Duration of cytopenia response

    Duration of cytopenia response will be assessed and measured according to the 2018 International Working Group (IWG) criteria with comparison between the Dec+THU treatment group and the placebo group

    Time frame: End of Treatment (Week 24) and Follow Up Visit 1 (Week 48)

  5. Changes in VAF in subgroups defined by cytopenias and baseline mutations

    VAF will be measured to compare changes in VAF in subgroups defined by baseline cytopenias and baseline mutations. DNA extracted from the peripheral blood will be sequenced after NGS library preparation and target-enrichment with a custom capture panel (Agilent Sure Select). Next Generation Sequencing (NGS) will be performed and the number of variant reads at a given position will be used to calculate the VAF. VAF will be a direct measure of the fraction of cells carrying the variant in the sample used for DNA extraction.

    Time frame: Baseline (Week 0), at the start of Cycle 4 Day 1 (Week 12) (each cycle is 28 days), End of Treatment (Week 24), Follow Up Visit 1 (Week 48) and Follow Up Visit 2 (Week 96)

  6. Changes in peripheral blood VAF

    Peripheral blood VAF will be measured at timepoints to compare changes in VAF between the Dec+THU treatment group and placebo group DNA extracted from the peripheral blood will be sequenced after NGS library preparation and target-enrichment with a custom capture panel (Agilent Sure Select). Next Generation Sequencing (NGS) will be performed and the number of variant reads at a given position will be used to calculate the VAF. VAF will be a direct measure of the fraction of cells carrying the variant in the sample used for DNA extraction.

    Time frame: Baseline (Week 0), at the start of Cycle 4 Day 1 (Week 12) (each cycle is 28 days), End of Treatment (Week 24), Follow Up Visit 1 (Week 48), Follow Up Visit 2 (Week 96)

  7. Changes in the levels of inflammatory cytokines between treatment groups in peripheral blood and bone marrow.

    Inflammatory cytokine profile changes will be compared between the Dec+THU treatment group and placebo group in peripheral blood and bone marrow. Serum and plasma will be extracted from participant bone marrow and peripheral blood samples for quantifying inflammatory cytokines levels to compare inflammatory cytokines profile changes between the treatment groups.

    Time frame: Baseline (Week 0), at the start of Cycle 4 Day 1 (Week 12) (each cycle is 24 weeks), End of Treatment (Week 24), Follow Up Visit 1 (Week 48), Follow Up Visit 2 (Week 96)

  8. Changes in bone marrow (BM) VAF

    This comparison will be made by measuring bone marrow VAF to determine if there are any changes between treatments groups at screening and end of treatment. DNA extracted from the bone marrow will be sequenced after NGS library preparation and target-enrichment with a custom capture panel (Agilent Sure Select). Next Generation Sequencing (NGS) will be performed and the number of variant reads at a given position will be used to calculate the VAF. VAF will be a direct measure of the fraction of cells carrying the variant in the sample used for DNA extraction.

    Time frame: Screening, End of Treatment (Week 24)

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Dec 2030, 48 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Apr 2026 → Dec 2026, primary completion Apr 2030 → Dec 2030 and completion Oct 2030 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 27, 2026
StartEst.
Dec 1, 2026was Apr 2026
Primary completionEst.
Dec 1, 2030was Apr 2030
CompletionEst.
Dec 2030was Oct 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 13, 2026→Dec 1, 2026
Nov 4, 2026
Primary completion
Apr 14, 2030→Dec 1, 2030
Nov 4, 2026
Study completion
Oct 2030→Dec 2030
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Apr 13, 2026→Dec 1, 2026
    Primary completion Apr 14, 2030→Dec 1, 2030
    Study completion Oct 2030→Dec 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07435636
Lead sponsor
Clinical Hub for Interventional Research (CHOIR)
Collaborators
Medical Research Future Fund, Australian National University, University of Auckland, New Zealand, Treebough Therapies, The University of New South Wales
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Professor Mark Polizzotto
Contact
mosaic.jcsmr@anu.edu.au
+61000000000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Decitabine · Tetrahydrouridine

Start the discussion